Danone (DN) 23rd annual dbAccess Global Consumer Conference summary
Event summary combining transcript, slides, and related documents.
23rd annual dbAccess Global Consumer Conference summary
2 Jun, 2026Market and category trends
Health and food connection is strengthening, with demographic trends like aging and cancer driving demand for science-based nutrition products.
Market fundamentals remain unchanged, with a focus on health foods and patient-centric approaches.
Productivity programs provide a competitive edge, enabling reinvestment and selective pricing amid inflation.
Product innovation and category mix, such as medical nutrition and high-protein offerings, are key growth drivers.
Channel mix is shifting from hypermarkets to pharmacies and specialty channels, improving margins.
Regional performance and innovation
North America yogurt market is buoyant, with protein-rich products showing lasting growth potential.
Gut health trends, including probiotics and kefir, are accelerating, with Activia achieving double-digit growth in some markets.
The Danone brand is underleveraged in the U.S. but is a strategic focus for future growth.
Progressive improvement in North American performance is expected as capacity and innovation ramp up.
Coffee creamers are stabilizing, with a trend toward naturalness emerging in the U.S. market.
Plant-based and specialized nutrition
Plant-based brands are being repositioned from ingredient-driven to benefit-driven, with new teams implementing successful European strategies in the U.S.
Progress in U.S. plant-based business is expected within 12 months as new strategies are deployed.
Adult medical nutrition is growing rapidly in Asia and Europe, with strong returns from investments in sales and go-to-market capabilities.
Expansion in China and the U.S. is supported by acquisitions like Kate Farms, enhancing reach and market access.
Latest events from Danone
- Q1 2026 delivered +2.7% LFL sales growth, but reported sales fell -2.0% on currency impacts.DN
Q1 202623 Apr 2026 - 4.5% LFL sales growth, margin up 44bps, and strong cash flow despite currency and recall impacts.DN
Q4 202520 Feb 2026 - Targets 3–5% sales growth, €3bn cash flow, and double-digit ROIC, led by health and protein focus.DN
CME 20243 Feb 2026 - 4.0% LFL sales growth, margin up, cash flow +11%, 2024 guidance confirmed.DN
Q2 20242 Feb 2026 - Q3 2024 like-for-like sales up 4.2%, with all regions and categories contributing to growth.DN
Q3 202419 Jan 2026 - Achieved 4.3% LFL sales growth, margin gains, and record €3.0bn free cash flow in FY 2024.DN
Q4 20247 Jan 2026 - Q1 2025 sales rose 4.3% LFL, led by strong growth in China and confirmed 2025 guidance.DN
Q1 202521 Dec 2025 - 4.2% LFL sales growth, margin up 49 bps, and strategic acquisitions highlight H1 2025.DN
Q2 20254 Nov 2025 - Q3 2025 sales rose 4.8% LFL, driven by volume/mix and strong China, North Asia & Oceania growth.DN
Q3 202528 Oct 2025